- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06255951
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
February 22, 2024 updated by: TYK Medicines, Inc
This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral Dose
Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of TY-9591 tablets in healthy subjects
Study Overview
Detailed Description
To evaluate the pharmacokinetics of TY-9591 tablets in healthy Chinese subjects after a single oral administration.
To evaluate the effects of itraconazole/rifampicin on the pharmacokinetics of TY-9591 and its metabolites D1 and D2 after oral administration of TY-9591 tablets.
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yali Liu
- Phone Number: 0754-88258290
- Email: fuyiyuanban@163.com
Study Contact Backup
- Name: Yali Liu
- Phone Number: 075488258290
- Email: fuyiyuanban@163.com
Study Locations
-
-
Shantou
-
Guangdong, Shantou, China, 515041
- Recruiting
- Yali Liu
-
Contact:
- liu yali
- Phone Number: 0754-88258290
- Email: fuyiyuanban@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female healthy adult subjects aged 18-45 years old (inclusive), in which male or female accounted for no less than 1/4 of the total number of subjects in each sequence.
- Body mass index (BMI) between 19.0 and 26.0 kg/m2 [BMI= weight (kg)/ height 2 (m2)] (including boundary values).
- Participants (including male participants) were infertile themselves, or agreed to use highly effective nonpharmacologic contraceptive methods or abstain completely from sex for 6 months after the last dose of self-medication.
- Subjects voluntarily participated and signed an informed consent form.
- Subjects had good communication with investigators and were able to complete the trial in accordance with the protocol.
Exclusion Criteria:
- Those with clinically significant abnormalities in physical examination, vital signs, routine laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function), 12-lead electrocardiogram, ophthalmic examination, abdominal color Doppler ultrasound (liver, bile duct, pancreas, spleen, kidney), etc.
- Persons with one or more positive results of human immunodeficiency virus (HIV) antibody, hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or treponema pallidum antibody (Anti-TP).
- smokers with an average of more than 10 cigarettes per day in the previous 3 months or habitual users of nicotine products who could not quit during the study.
- Heavy drinking or regular drinking in the 3 months before the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine); Or alcohol breath test results on admission > 0.0 mg/100 mL and those who could not abstain from alcohol during the experiment.
- those who consumed excessive amounts of tea, coffee, and/or caffeinated beverages (average > 8 cups/day, 250 mL/cup) in the 3 months before the screening period, and those who could not stop using them during the study period.
- those who took dragon fruit, mango, grapefruit, chocolate, any food or beverage containing caffeine, diet rich in xanthine, and other special diets affecting drug absorption, distribution, metabolism, and excretion within 7 days before taking the drug.
- Use of any drugs that inhibit or induce the liver CYP3A4 enzyme (see Appendix II), herbs, or foods containing herbal ingredients within 30 days before the screening period.
- taking any medicine (including Chinese herbal medicine and health supplements) within 14 days before taking the test drug.
- enrollment in any drug clinical trial within 3 months before the screening period.
- Subjects who may not be able to complete the study for other reasons or who are considered unsuitable for the study by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Itraconazole
|
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence).
PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
|
Experimental: Rifampicin
|
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence).
PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t)
Time Frame: through study completion,an average of 6 months
|
Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t)
|
through study completion,an average of 6 months
|
Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permit
Time Frame: through study completion,an average of 6 months
|
Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permit
|
through study completion,an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to peak concentration (Tmax) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
Time to peak concentration (Tmax) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
The half-life of elimination phase (t1/2) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
The half-life of elimination phase (t1/2) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
elimination rate constant (λz) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
elimination rate constant (λz) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
apparent clearance rate (CL/F) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
apparent clearance rate (CL/F) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
apparent volume of distribution (Vd/F) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
apparent volume of distribution (Vd/F) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
mean retention time (MRT) of TY-9591 and its metabolites D1 and D2
Time Frame: through study completion,an average of 6 months
|
mean retention time (MRT) of TY-9591 and its metabolites D1 and D2
|
through study completion,an average of 6 months
|
Cmax ratio of metabolites to original drug
Time Frame: through study completion,an average of 6 months
|
Cmax ratio of metabolites to original drug
|
through study completion,an average of 6 months
|
AUC ratio of metabolites to original drug
Time Frame: through study completion,an average of 6 months
|
AUC ratio of metabolites to original drug
|
through study completion,an average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: yali liu, Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 4, 2024
Primary Completion (Estimated)
July 8, 2024
Study Completion (Estimated)
August 5, 2024
Study Registration Dates
First Submitted
January 17, 2024
First Submitted That Met QC Criteria
February 3, 2024
First Posted (Actual)
February 13, 2024
Study Record Updates
Last Update Posted (Estimated)
February 26, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inducers
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- 14-alpha Demethylase Inhibitors
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
- Itraconazole
Other Study ID Numbers
- TYKM1601105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on Itraconazole
-
University of Maryland, BaltimoreCompleted
-
University of Alabama at BirminghamWashington University School of Medicine; University of California, DavisCompletedInvasive Fungal InfectionsUnited States, Panama
-
Johns Hopkins UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
Sara BotrosCompleted
-
Pulmatrix Inc.Completed
-
University of Kansas Medical CenterUniversity of Texas, Southwestern Medical Center at DallasRecruitingBarrett Oesophagitis With DysplasiaUnited States
-
Halcygen Pharmaceuticals LimitedCompletedOnychomycosisUnited States
-
H. Lundbeck A/SCompletedCytochrome P450 InteractionUnited Kingdom, United States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedOnychomycosisUnited States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedNon-small Cell Lung Cancer MetastaticUnited States